Immunic (IMUX) Scheduled to Post Earnings on Wednesday

Immunic (NASDAQ:IMUX - Get Free Report) is set to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect Immunic to post earnings of ($0.27) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.03. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Trading Up 2.3 %

Shares of Immunic stock traded up $0.03 during trading on Thursday, reaching $1.33. The company's stock had a trading volume of 134,643 shares, compared to its average volume of 802,756. The firm has a market cap of $119.81 million, a PE ratio of -0.63 and a beta of 1.93. The company has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $1.26. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on IMUX shares. Brookline Capital Management reissued a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Friday, April 5th. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a report on Saturday, April 27th.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.